Department of Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology Indore (IITI), Simrol, 453552, Indore, India.
Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Numazu-shi, Shizuoka, Japan.
Arch Microbiol. 2022 Sep 5;204(10):603. doi: 10.1007/s00203-022-03194-0.
Lung cancer, the most prevalent gender-independent tumor entity in both men and women, is among the leading cause of cancer-related deaths worldwide. Despite decades of effort in developing improved therapeutic strategies including immunotherapies and novel chemotherapeutic agents, only modest improvements in outcome and long-term survival of lung cancer patients have been achieved. Therefore, exploring new and exceptional sources for bioactive compounds that might serve as anti-cancer agents might be the key to improving lung cancer therapy. On account of diverse forms, cyanobacteria might serve as a potential source for compounds with potential therapeutic applicability against malignant disorders, including cancer. The assorted arrays of metabolic mechanisms synthesize a plethora of bioactive compounds with immense biological potential. These compounds have been proven to be effective against various cancer cell lines and xenograft animal models. The present review provides an overview of the most promising cyanobacteria-derived bioactive compounds proven to exhibit anti-cancer properties in in-vitro and in-vivo studies and highlights their applicability as potential therapeutic agents with a focus on their anti-lung cancer properties.
肺癌是男性和女性中最常见的与性别无关的肿瘤实体，是全球癌症相关死亡的主要原因之一。尽管几十年来一直在努力开发改进的治疗策略，包括免疫疗法和新型化疗药物，但肺癌患者的预后和长期生存仅取得了适度的改善。因此，探索新的、特殊的生物活性化合物来源，可能是改善肺癌治疗的关键。由于蓝细菌的多种形式，它可能是具有潜在治疗应用价值的化合物的潜在来源，包括癌症。各种各样的代谢机制合成了大量具有巨大生物学潜力的生物活性化合物。这些化合物已被证明对各种癌细胞系和异种移植动物模型有效。本综述概述了在体外和体内研究中已被证明具有抗癌特性的最有前途的蓝细菌衍生的生物活性化合物，并强调了它们作为潜在治疗剂的适用性，重点是它们的抗肺癌特性。
